Nutraponia Therapeutics, LLC
Clinical-stage (Phase 2a) therapeutics company developing oral combination therapies intended to relieve cancer-related pain while providing structured nutritional support for patients with cancer cachexia.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Oral analgesic–nutritional combination (small‑volume liquid)
A small‑volume, readily digestible oral liquid combining an opioid analgesic active with a structured lipid nutrient matrix intended to provide analgesia and approximately 100 kcal of supplemental energy for patients with cancer cachexia. Evaluated in a Phase I PK/tolerability study in healthy volunteers.
Oral analgesic–nutritional combination (small‑volume liquid)
A small‑volume, readily digestible oral liquid combining an opioid analgesic active with a structured lipid nutrient matrix intended to provide analgesia and approximately 100 kcal of supplemental energy for patients with cancer cachexia. Evaluated in a Phase I PK/tolerability study in healthy volunteers.
Services
Provision of scientific background, development updates, and collaboration inquiries for healthcare professionals.
Provision of scientific background, development updates, and collaboration inquiries for healthcare professionals.
Expertise Areas
- Clinical trial management (Phase I–III)
- Oral formulation development
- Nutritional therapeutics for cachexia
- Pharmacokinetics and bioanalysis
Key Technologies
- Oral small‑volume liquid dosage forms
- Structured lipid matrices for enhanced gut absorption
- Opioid analgesic pharmacology (mu/kappa/delta agonists)
- Crossover PK study design
News & Updates
Investor and scientific presentation (March 2026) covering unmet need in cancer cachexia, NT1000 development approach, Phase I PK results, projected development timeline, regulatory pathway, and commercial strategy.
Investor and scientific presentation (March 2026) covering unmet need in cancer cachexia, NT1000 development approach, Phase I PK results, projected development timeline, regulatory pathway, and commercial strategy.